AAD

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

Retrieved on: 
Friday, March 8, 2024
Oncology, Health, Stem Cells, Genetics, General Health, Research, Science, Skin cancer, DMT, NPV, MD, Melanoma, Skin, TP53, Paul Khavari, AAD, NOTCH1, Abstract, Patient, Journal, Trial of the century, DNA, American Academy

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.
  • “This real-world clinical study demonstrates that the DMT can help clinicians improve outcomes for cutaneous melanomas in patients of all skin types,” commented Dr. Skelsey.
  • The research found that somatic mutations in healthy-appearing sun-exposed skin indicate an increased risk for skin cancer.
  • Furthermore, these mutations capture skin cancer risk information that is not accounted for by other risk factors.

Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Retrieved on: 
Friday, March 8, 2024
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Skin, Week, Psoriasis, American Academy of Dermatology, FDA, Atopic dermatitis, Validation, Treatment, AAD, JD, White, Alaska Natives, American Indians, American Academy, Pharmaceutical industry

“Importantly, approximately 50% of patients who enrolled in the ADORING pivotal trials had skin of color, a particularly high representation in clinical trials.

Key Points: 
  • “Importantly, approximately 50% of patients who enrolled in the ADORING pivotal trials had skin of color, a particularly high representation in clinical trials.
  • Secondary endpoints in the pivotal studies included the proportion of patients who achieved ≥75% improvement in the Eczema Area and Severity Index (EASI75).
  • Baseline Demographics Across ADORING Pivotal Phase 3 Trials:
    Approximately 50% of patients who enrolled had skin of color.
  • New Data on VTAMA cream from ADORING 1 and ADORING 2 for the Treatment of AD in Patients with Skin of Color Presented at AAD 2024 – Primary and Secondary Endpoints:

Kenvue to Showcase 22 New Sets of Clinical Data at American Academy of Dermatology Association Meeting

Retrieved on: 
Thursday, March 7, 2024
Retail, Health, Home Goods, Other Health, Clinical Trials, General Health, Cream, Name, Skin, Woman, Efficacy, Psoriasis, Pigment, Education, Quality of life, Dermatology, Skin care, Risk, AAD, Itch, Dermatitis, Science, San Diego Convention Center, Inc., Theatre, American Academy, Cosmetics

Kenvue will also offer hands-on experiences in exhibit-floor Booth 2511, featuring products that are household names, including those from the Neutrogena®, Aveeno®, NeoStrata®, Lubriderm®, BAND-AID® Brand and Rogaine®1 portfolios.

Key Points: 
  • Kenvue will also offer hands-on experiences in exhibit-floor Booth 2511, featuring products that are household names, including those from the Neutrogena®, Aveeno®, NeoStrata®, Lubriderm®, BAND-AID® Brand and Rogaine®1 portfolios.
  • Additional data to be presented at AAD demonstrates the benefits of Kenvue’s formulations for skin hydration, sun protection and acne control.
  • Demonstrating the Clinical Effectiveness of Mineral Sunscreens in Protecting the Skin Against Ultraviolet A (UVA) Radiation-Induced Pigmentation; Shyr TC, et al.
  • On Friday and Saturday, Kenvue experts and key opinion leaders will also host R&D Theater presentations in the booth.

LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas

Retrieved on: 
Wednesday, March 6, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Adolescence, EVP, American Academy of Dermatology, Ichthyosis, Atopic dermatitis, Pain, Dermatology, Calendar, Annual general meeting, AAD, Safety, Pharmacokinetics, Abstract, CHE, Congress, LEO, ASCEND, Leo Pharma, American Academy, Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a breadth of new data on moderate-to-severe chronic hand eczema (CHE), congenital ichthyosis (CI) and atopic dermatitis (AD) at the upcoming 82nd American Academy of Dermatology (AAD) Annual Meeting.
  • The event is being held from March 8th to 12th in San Diego, California.
  • “Our growing body of clinical evidence reinforces our passion and commitment to advancing the standard of care in medical dermatology,” said Kreesten Meldgaard Madsen, LEO Pharma’s Chief Development Officer.
  • I am proud that we can follow up on our 2023 AAD program with this level of critical data,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma.

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 4, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Cream, American Academy of Dermatology, Safety, Randomness, Atopic dermatitis, Ageing, Autoimmunity, Treatment, Dermatology, Inflammation, AAD, Vitiligo, Prurigo, Hidradenitis suppurativa, Abstract, American Academy, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.
  • “We are pleased to convene at this year’s AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • “Our presence at this year’s meeting showcases Incyte’s commitment to find solutions for patients where there continues to be critical unmet needs.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Retrieved on: 
Thursday, February 29, 2024
Research, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Cosmetics, Retail, Science, Other Science, Adapalene, Education, Investment, Growth, Calcineurin, Skin, Database, STAR, FY, Aesthetics, Acne, Sculptra, Prurigo nodularis, Defense, FACE, European Medicines Agency, Council, Congress, Pimple, GAIN, Atopic dermatitis, Sleep, ESG, Benzoyl peroxide, George Washington University, American Academy, Marketing, Health Canada, Core, Patient satisfaction, FDA, Quality of life, Ageing, Food, IL-31, Risk, AAD, Patient, Restylane, Pharmaceutical industry

2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.

Key Points: 
  • 2023 margin expansion was driven by gains from premiumization, structural cost savings, and operating expenses leverage, partially offset by nemolizumab investments.
  • On 26 June 2023, Galderma announced a private placement of approximately 1 B USD from a group consisting of current shareholders, new investors, as well as management.
  • Cetaphil, with over 75 years of heritage in sensitive skincare, surpassed a record 1 B USD in net sales in 2023.
  • In 2023, Galderma further consolidated its ESG profile by rolling out a dedicated executive-level ESG oversight and instituting the ESG Council.

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, February 28, 2024
Research, Clinical Trials, Biotechnology, Managed Care, Health, Cosmetics, Pharmaceutical, Retail, Science, Acne, Nemolizumab, Pacific Ocean, Atopic dermatitis, Prurigo nodularis, Hyperhidrosis, Dermatology, Skin, Consultant, AAD, Marriott Marquis, Safety, Patient, Itch, START, American Academy, Medical device

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

Key Points: 
  • Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.
  • “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action.
  • The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.
  • *All presenters are paid consultants or employees of Galderma.

An Invitation to Innovaderm’s 5th Breakfast Event, This Year’s Focus is on Alopecia Areata (AA)

Retrieved on: 
Thursday, February 22, 2024
General Health, Health, Clinical Trials, Practice Management, Breakfast, Alopecia areata, Research, Biotechnology, Dermatology, Internet, Skin, AA, AAD, Patient, American Academy

This year, the event will focus on the world of Alopecia Areata (AA).

Key Points: 
  • This year, the event will focus on the world of Alopecia Areata (AA).
  • They will be sharing thoughts on “Clinical Evaluations and Current Treatments for AA” and “Experimental and Future Treatments of AA” respectively.
  • The Breakfast Event will serve as a platform to engage in insightful discussions and network with industry professionals, clinicians, and peers in dermatology clinical research.
  • If you plan to attend AAD in San Diego, we highly recommend reserving your place at our Breakfast Event without further ado.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

Retrieved on: 
Saturday, March 9, 2024
Pustulosis palmaris et plantaris, Psoriasis, CPU socket, Aes, Headache, Diarrhea, Amgen, Pain, Pediatrics, DLQI, Skin, Nausea, Vomiting, Queen's University, AMGN, AAD, Safety, University, FRCPC, University of Alberta, PASI, Dermatology Life Quality Index, Patient, PST, Scalp, Ageing, Abdominal pain, Poster, American Academy, Pharmaceutical industry

THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.                                     

Key Points: 
  • These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
  • "These data reflect Amgen's commitment to exploring new ways to treat inflammatory skin disease," said Ponda Motsepe-Ditshego, vice president, Global Medical, at Amgen.
  • Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in patients for up to one year.
  • Findings will be presented as a late-breaking oral presentation on Saturday, March 9 at 9:20 a.m. PST.

Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study

Retrieved on: 
Saturday, March 9, 2024
MPC, Woman, LDH, CMO, LOS, Hair loss, Blood, Pattern hair loss, Biopsy, Fur, Skin, Data, Annual general meeting, B cell, AAD, Patient, Clinical trial, Inhibitor, American Academy, Pharmaceutical industry

LOS ANGELES, March 9, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, today presented positive translational and Phase 1 clinical data demonstrating the company's novel small molecule therapy PP405 reactivates dormant hair follicle stem cells to trigger hair growth. Data were presented in a late-breaking oral session of the American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego, titled Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo.

Key Points: 
  • Data were presented in a late-breaking oral session of the American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego, titled Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo.
  • "The translational data derived from our ex vivo studies on human facelift skin have been further validated in a Phase 1 first-in-human clinical trial demonstrating PP405 effectively reactivates dormant hair follicle stem cells," said Daniel Gil, Ph.D., CEO of Pelage Pharmaceuticals.
  • The LDH activity corresponded with a significant increase in Ki67 signal in the hair bulge, indicating a proliferative response of the hair follicle stem cells.
  • PP405 may also have applications for other forms of alopecia, including telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.